TNFSF10 and glioblastoma: The therapeutic efficacy was proven by in vitro and in vivo assays using primary patient-derived glioblastoma models, which decreased tumor volume and prolonged survival time, as well as limiting off-target cytotoxicity with the controlled expression of the suicide inductor TRAIL [97].